Loyal vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Loyal is a veterinary biotech developing FDA-regulated longevity drugs for dogs; its lead drug LOY-001 received FDA reasonable expectation of effectiveness — the first longevity drug for any species to do so; raised $45M; founded by Celine Halioua.
About
Loyal is a veterinary biotechnology company founded in 2020 by Celine Halioua and headquartered in San Francisco, California. The company is developing pharmaceutical treatments designed to extend the healthspan and lifespan of dogs — large breeds in particular, which age faster and live shorter lives than small breeds. Loyal's approach is grounded in the biology of aging: targeting the hormonal, metabolic, and cellular mechanisms that drive age-related decline in dogs, with the goal of creating FDA-approved drugs that add healthy years to companion animals' lives.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.